We are analyzing https://link.springer.com/article/10.1007/s00280-015-2886-5.

Title:
Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer | Cancer Chemotherapy and Pharmacology
Description:
Monocyte chemoattractant protein 1 (MCP-1/CCL-2) is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages. It plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of MCP-1/CCL-2 in gastric cancer patients. A total of 78 patients diagnosed with gastric cancer were enrolled in this study. Serum MCP-1/CCL-2 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis. The median age at diagnosis was 60 years, range 21–84 years. The baseline serum MCP-1/CCL-2 concentrations of the gastric cancer patients were significantly higher than of healthy subjects (p < 0.001). The known clinical variables including gender, age, site of lesion, histopathology, tumor size, lymph node involvement, and stage of disease were not found to be correlated with serum MCP-1/CCL-2 concentrations (p > 0.05). However, a significant relationship was shown between serum MCP-1/CCL-2 levels and response to chemotherapy (p = 0.05). Chemotherapy non-responsive patients had higher serum MCP-1/CCL-2 concentrations. Serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival (p = 0.53 and p = 0.39, respectively). Elevated circulating MCP-1/CCL-2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer. However, serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cancer, article, mcpccl, gastric, patients, serum, chemotherapy, pubmed, monocyte, concentrations, access, privacy, cookies, content, chemoattractant, protein, predictive, karabulut, publish, research, search, circulating, factor, tas, google, scholar, data, information, log, journal, elevated, level, unfavorable, platinum, october, faruk, serilmez, levels, age, subjects, cell, open, ccl, discover, cas, central, download, author, istanbul, springer,

Topics {✒️}

month download article/chapter serum mcp-1/ccl-2 concentrations monocyte chemotactic protein-1/ccl2 serum mcp-1/ccl-2 levels monocyte chemoattractant protein-1 taxane-based combination chemotherapy article cancer chemotherapy full article pdf gastric cancer patients privacy choices/manage cookies preoperative serum ccl2 related subjects unfavorable predictive factor murat serilmez potent chemotactic factor gastric cancer european economic area lymph node involvement ethics declarations conflict conditions privacy policy cc chemokine family article tas accepting optional cookies serum levels check access author correspondence instant access mcp-1/ccl-2 article log journal finder publish healthy subjects oncology research hospital cancer patients article cite pharmacology aims chemotherapy based faruk tas chemokine mcp-1 privacy policy personal data significantly higher books a optional cookies manage preferences senem karabulut clinical significance cancer subscription content similar content

Questions {❓}

The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
         description: Monocyte chemoattractant protein 1 (MCP-1/CCL-2) is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages. It plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of MCP-1/CCL-2 in gastric cancer patients. A total of 78 patients diagnosed with gastric cancer were enrolled in this study. Serum MCP-1/CCL-2 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis. The median age at diagnosis was 60 years, range 21–84 years. The baseline serum MCP-1/CCL-2 concentrations of the gastric cancer patients were significantly higher than of healthy subjects (p < 0.001). The known clinical variables including gender, age, site of lesion, histopathology, tumor size, lymph node involvement, and stage of disease were not found to be correlated with serum MCP-1/CCL-2 concentrations (p > 0.05). However, a significant relationship was shown between serum MCP-1/CCL-2 levels and response to chemotherapy (p = 0.05). Chemotherapy non-responsive patients had higher serum MCP-1/CCL-2 concentrations. Serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival (p = 0.53 and p = 0.39, respectively). Elevated circulating MCP-1/CCL-2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer. However, serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival.
         datePublished:2015-10-23T00:00:00Z
         dateModified:2015-10-23T00:00:00Z
         pageStart:127
         pageEnd:131
         sameAs:https://doi.org/10.1007/s00280-015-2886-5
         keywords:
            MCP-1/CCL-2
            Serum
            Gastric cancer
            Predictive
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-015-2886-5/MediaObjects/280_2015_2886_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-015-2886-5/MediaObjects/280_2015_2886_Fig2_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:77
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Faruk Tas
               affiliation:
                     name:University of Istanbul
                     address:
                        name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Senem Karabulut
               affiliation:
                     name:University of Istanbul
                     address:
                        name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Murat Serilmez
               affiliation:
                     name:University of Istanbul
                     address:
                        name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mehmet Karabulut
               affiliation:
                     name:Bakirkoy Dr Sadi Konuk Training and Research Hospital
                     address:
                        name:Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Derya Duranyildiz
               affiliation:
                     name:University of Istanbul
                     address:
                        name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
      description: Monocyte chemoattractant protein 1 (MCP-1/CCL-2) is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages. It plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of MCP-1/CCL-2 in gastric cancer patients. A total of 78 patients diagnosed with gastric cancer were enrolled in this study. Serum MCP-1/CCL-2 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis. The median age at diagnosis was 60 years, range 21–84 years. The baseline serum MCP-1/CCL-2 concentrations of the gastric cancer patients were significantly higher than of healthy subjects (p < 0.001). The known clinical variables including gender, age, site of lesion, histopathology, tumor size, lymph node involvement, and stage of disease were not found to be correlated with serum MCP-1/CCL-2 concentrations (p > 0.05). However, a significant relationship was shown between serum MCP-1/CCL-2 levels and response to chemotherapy (p = 0.05). Chemotherapy non-responsive patients had higher serum MCP-1/CCL-2 concentrations. Serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival (p = 0.53 and p = 0.39, respectively). Elevated circulating MCP-1/CCL-2 level may be an unfavorable predictive factor to chemotherapy based on platinum and taxane in patients with gastric cancer. However, serum MCP-1/CCL-2 concentrations were not associated with prognosis on both progression-free and overall survival.
      datePublished:2015-10-23T00:00:00Z
      dateModified:2015-10-23T00:00:00Z
      pageStart:127
      pageEnd:131
      sameAs:https://doi.org/10.1007/s00280-015-2886-5
      keywords:
         MCP-1/CCL-2
         Serum
         Gastric cancer
         Predictive
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-015-2886-5/MediaObjects/280_2015_2886_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-015-2886-5/MediaObjects/280_2015_2886_Fig2_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:77
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Faruk Tas
            affiliation:
                  name:University of Istanbul
                  address:
                     name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Senem Karabulut
            affiliation:
                  name:University of Istanbul
                  address:
                     name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Murat Serilmez
            affiliation:
                  name:University of Istanbul
                  address:
                     name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mehmet Karabulut
            affiliation:
                  name:Bakirkoy Dr Sadi Konuk Training and Research Hospital
                  address:
                     name:Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Derya Duranyildiz
            affiliation:
                  name:University of Istanbul
                  address:
                     name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:77
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Istanbul
      address:
         name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
         type:PostalAddress
      name:University of Istanbul
      address:
         name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
         type:PostalAddress
      name:University of Istanbul
      address:
         name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
         type:PostalAddress
      name:Bakirkoy Dr Sadi Konuk Training and Research Hospital
      address:
         name:Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
         type:PostalAddress
      name:University of Istanbul
      address:
         name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Faruk Tas
      affiliation:
            name:University of Istanbul
            address:
               name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Senem Karabulut
      affiliation:
            name:University of Istanbul
            address:
               name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
               type:PostalAddress
            type:Organization
      name:Murat Serilmez
      affiliation:
            name:University of Istanbul
            address:
               name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
               type:PostalAddress
            type:Organization
      name:Mehmet Karabulut
      affiliation:
            name:Bakirkoy Dr Sadi Konuk Training and Research Hospital
            address:
               name:Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
               type:PostalAddress
            type:Organization
      name:Derya Duranyildiz
      affiliation:
            name:University of Istanbul
            address:
               name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
      name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
      name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
      name:Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
      name:Institute of Oncology, University of Istanbul, Istanbul, Turkey
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(49)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.02s.

LINK . SPRINGER . COM {}